ES2183131T3 - Anticuerpos anti-cd18 utilizados contra el ictus cerebral. - Google Patents

Anticuerpos anti-cd18 utilizados contra el ictus cerebral.

Info

Publication number
ES2183131T3
ES2183131T3 ES97903790T ES97903790T ES2183131T3 ES 2183131 T3 ES2183131 T3 ES 2183131T3 ES 97903790 T ES97903790 T ES 97903790T ES 97903790 T ES97903790 T ES 97903790T ES 2183131 T3 ES2183131 T3 ES 2183131T3
Authority
ES
Spain
Prior art keywords
antibodies used
used against
against cerebral
cerebral ictus
ictus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97903790T
Other languages
English (en)
Inventor
Martin M Bednar
Cordell E Gross
G Roger Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Vermont
Genentech Inc
Original Assignee
University of Vermont
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Vermont, Genentech Inc filed Critical University of Vermont
Application granted granted Critical
Publication of ES2183131T3 publication Critical patent/ES2183131T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBE UN METODO PARA MEJORAR EL RESULTADO CLINICO EN EL ATAQUE ISQUEMICO FOCAL EN UN MAMIFERO INCREMENTANDO EL FLUJO SANGUINEO CEREBRAL Y/O REDUCIENDO EL TAMAÑO DEL INFARTO, QUE IMPLICA LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UN ANTICUERPO ANTI CD18 AL MAMIFERO, SIN QUE SE HAYA RETIRADO LA OBSTRUCCION ARTERIAL.
ES97903790T 1996-01-23 1997-01-11 Anticuerpos anti-cd18 utilizados contra el ictus cerebral. Expired - Lifetime ES2183131T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58998296A 1996-01-23 1996-01-23

Publications (1)

Publication Number Publication Date
ES2183131T3 true ES2183131T3 (es) 2003-03-16

Family

ID=24360401

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97903790T Expired - Lifetime ES2183131T3 (es) 1996-01-23 1997-01-11 Anticuerpos anti-cd18 utilizados contra el ictus cerebral.

Country Status (13)

Country Link
EP (2) EP0877626B1 (es)
JP (1) JP4864175B2 (es)
AR (1) AR005535A1 (es)
AT (1) ATE222774T1 (es)
AU (1) AU724449B2 (es)
CA (1) CA2242414C (es)
DE (1) DE69714966T2 (es)
DK (1) DK0877626T3 (es)
ES (1) ES2183131T3 (es)
IL (1) IL125255A (es)
PT (1) PT877626E (es)
WO (1) WO1997026912A2 (es)
ZA (1) ZA97257B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
AU4000500A (en) * 1999-02-17 2000-09-04 Genentech Inc. Co-administration of a thrombolytic and an anti-cd18 antibody
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
WO2001070260A1 (en) * 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Cd18-binding antibodies inhibit stenosis-related disorders
JP2003527439A (ja) 2000-03-17 2003-09-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ１８抗体と抗ｃｃｒ２抗体の混合物を用いる狭窄および再狭窄を抑制する方法
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
DK3095793T3 (da) 2003-07-28 2020-05-25 Genentech Inc Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
WO2005058251A2 (en) 2003-12-15 2005-06-30 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
WO2006004988A2 (en) * 2004-06-30 2006-01-12 Mayo Foundation For Medical Education And Research B7-dc binding antibody
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
US7501119B2 (en) 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
RU2474585C2 (ru) 2007-01-22 2013-02-10 Дженентек, Инк. Осаждение и очистка белков полиэлектролитами
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
ES2533266T5 (es) 2007-10-30 2018-04-18 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
BRPI0823046B1 (pt) 2008-08-14 2021-12-14 Genentech, Inc Método para purificar um anticorpo monoclonal de uma composição compreendendo o anticorpo monoclonal e pelo menos uma proteína de ovário de hamster chinês (chop)
CN103599541A (zh) 2008-09-10 2014-02-26 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
JP2012511929A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン 攪拌タンク反応器及び方法
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
EP2400992B1 (en) 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
SI2473617T1 (sl) 2009-09-01 2020-07-31 F. Hoffmann-La Roche Ag Izboljšano prečiščevanje beljakovin z modificirano elucijo beljakovine A
EP2550018B1 (en) 2010-03-22 2019-02-27 F.Hoffmann-La Roche Ag Compositions and methods useful for stabilizing protein-containing formulations
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
WO2011146394A1 (en) 2010-05-17 2011-11-24 Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
CA2800728C (en) 2010-05-28 2020-10-27 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
CA2808185A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US20130012689A1 (en) 2011-07-08 2013-01-10 Emd Millipore Corporation Depth Filters For Disposable Biotechnological Processes
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
BR112014023176B1 (pt) 2012-03-27 2021-09-28 Genentech, Inc. Métodos de produção de uma proteína recombinante
EP2849723B1 (en) 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
CA2898146C (en) 2012-12-19 2020-12-01 Charles Andrew BOSWELL Methods and compositions for radiohalogen protein labeling
AU2015287760B2 (en) 2014-07-09 2019-06-20 Genentech, Inc. pH adjustment to improve thaw recovery of cell banks
EP3436610A1 (en) 2016-03-29 2019-02-06 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
AU2017382281B2 (en) 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
HRP20240584T1 (hr) 2018-07-03 2024-07-19 Bristol-Myers Squibb Company Postupak proizvodnje rekombinantnih proteina
WO2020076776A1 (en) 2018-10-10 2020-04-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
TWI856084B (zh) 2019-04-01 2024-09-21 美商建南德克公司 用於穩定含有蛋白質之配方之組合物及方法
EP3953380A4 (en) 2019-04-12 2023-01-25 Geltor, Inc. RECOMBINATION ELASTIN AND ASSOCIATED PRODUCTION
EP4007808A1 (en) 2019-08-01 2022-06-08 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
EP4217383A1 (en) 2020-09-22 2023-08-02 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1069182A1 (en) * 1992-07-16 2001-01-17 Icos Corporation Alleviation of symptoms associated with inflammatory disease states, using antibodies to CD18
WO1994012214A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18

Also Published As

Publication number Publication date
DE69714966D1 (de) 2002-10-02
EP0877626A2 (en) 1998-11-18
AR005535A1 (es) 1999-06-23
ZA97257B (en) 1998-07-14
EP1297847A2 (en) 2003-04-02
AU1827397A (en) 1997-08-20
EP1297847A3 (en) 2003-05-07
IL125255A (en) 2002-02-10
CA2242414C (en) 2012-01-03
JP2000517289A (ja) 2000-12-26
DK0877626T3 (da) 2002-12-30
EP0877626B1 (en) 2002-08-28
AU724449B2 (en) 2000-09-21
PT877626E (pt) 2003-01-31
IL125255A0 (en) 1999-03-12
ATE222774T1 (de) 2002-09-15
CA2242414A1 (en) 1997-07-31
WO1997026912A3 (en) 1997-10-09
WO1997026912A2 (en) 1997-07-31
DE69714966T2 (de) 2003-04-24
JP4864175B2 (ja) 2012-02-01

Similar Documents

Publication Publication Date Title
ES2183131T3 (es) Anticuerpos anti-cd18 utilizados contra el ictus cerebral.
KR910004187A (ko) 세트랄린을 사용한 조기사정의 치료방법
ES2170126T3 (es) Composiciones cosmeticas espesadas.
ATE19733T1 (de) Hydroxysubstituierte benzothiazolsulfonamide fuer die topische behandlung von intraokularer hypertension.
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
BR9705207A (pt) Anel de vedação metálico para junta tubular.
EP1491183A3 (fr) Utilisation d'un extrait d'au moins un végétal de la famille des Rosacées
DK0625050T3 (da) TGF-BETA til forbedring af regenerering af nervevæv
DE59605848D1 (de) Transparente, schnell freisetzende zubereitungen von nichtsteroidalen analgetica
ES2195151T3 (es) Dispositivo de mejora de aporte o de muestreo de agentes transdermicos.
CA2222303A1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
DE69232150D1 (de) Behandlung von Augenhochdruck mit Betablockern und Prostansäurederivaten
EP0793489A4 (en) Compositions for the treatment of skin disorders
EE03223B1 (et) Kiiretoimelist dihüdropüridiinühendit sisaldav farmatseutiline emulsioon vererõhu alandamiseks ja selle valmistamise protsess
NO900251L (no) Fremgangsmaate for behandling eller hindring av intrinsik aldret hud med retinoider.
ES2102424T3 (es) Composicion de eliminacion de tapones queratosicos.
AR247984A1 (es) Metodo para la preparacion de una composicion sinergica que tiene actividad antiplaca o antigingivitis
ECSP941082A (es) Procedimiento para la preparacion de la sal sodica cristalina adhidra de 5- cloro-3 (2-tenoli)-2- oxindol-1 carboxamida
FR2413084A1 (fr) Composition cosmetique pour le demaquillage des yeux
BG102064A (en) Method for increasing the retinal blood circulation
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
DE69325174D1 (de) Ophthalmische zusammensetzungen und verfahren zu ihrer konservierung und anwendung
BE1001056A3 (fr) Association de derives de pyrimidine et de retinoides en composants separes pour induire et stimuler la croissance des cheveux et diminuer leur chute.
GB1495289A (en) Pharmaceutically active proteinaceous compounds